A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

← catalyst calendar

NCT07794579 · readout ≤ 1,095 d

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase

Phase 3

Status

Not yet recruiting

Study type

Interventional

Design

Randomized · Double · Treatment

Enrollment

2,001estimated

Sites

179

Countries

Argentina, China, Czechia +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-31

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

Sep 2026

estimated

When the study began enrolling

Primary completion

Aug 2029

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2030

estimated

The whole study's end, after follow-up

First posted

2026-08-31

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-31

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Overweight
Prediabetic State
Prehypertension
Obesity, Abdominal

Interventions

Drug: Orforglipron — also filed as LY3502970
Drug: Placebo

Primary outcome

what the primary-completion date above is the date OF

Time to Onset of Obesity Related Complications or Class 1 Obesity

measured Baseline to Week 104

LLY · their whole pipeline · Overweight readouts · Who in Congress owns LLY? · Executive-branch trades in LLY

LLY's other studiesmost recently updated first

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes Phase 2 · Terminated
A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants Phase 1 · Not yet recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder Phase 3 · Not yet recruiting
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease Phase 1 · Not yet recruiting
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems Phase 3 · Not yet recruiting

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed